COVID-19
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
The race toward a COVID-19 vaccine is focused around scientific development right now, but companies also need to be planning for manufacturing.
Numerous biopharma companies are testing or working to develop drugs and vaccines. But what is a bit unusual is the number of staffers at biotech and pharma companies and health care involved as participants in studies and clinical trials.
Researchers found that certain individuals who have never been exposed to COVID-19 appear to have “helper” T cells that are capable of recognizing and responding to the virus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
The warning came only a few hours after the FDA rescinded Emergency Use Authorization (EUA) for hydroxychloroquine and chloroquine for the treatment of COVID-19.
Low doses of a long-used steroid known as dexamethasone could be the solution to improving the chances of patients who become seriously ill from COVID-19 infection and require some kind of breathing assistance.
The FDA indicated that, based on new evidence, there was not enough supporting evidence for the two drugs to be considered effective in treating COVID-19.
The U.K. pharma giant struck a deal with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of the preventative medication by the end of 2020 – if it clears the clinic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.
PRESS RELEASES